French pharmaceutical company to open 15K-sq.-ft. Devens research center

French pharmaceutical company Seqens will unveil its new research and development center in Devens on January 31. The new facility will be roughly 15,000 square feet and used for discovery and development of new drugs and therapeutics. 

The multinational company has 24 manufacturing sites and 10 research and development centers. It has an office in Newburyport. 

The new facility comes one year after SK Capital Partners of New York City became majority shareholder in the company in December of 2021 and subsequently merged Seqens with Wavelength Pharmaceuticals of Israel. SK Capital specializes in materials, chemicals and pharmaceutical companies.